ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

The licensing of &bgr;-interferons for the treatment of multiple sclerosis (MS) has created a dilemma for the UK National Health Service (NHS). There is now a therapy available for a disease where management has traditionally been limited to symptomatic treaments; however, it comes with a large price tag attached. At a time when rationing is becoming a reality in the NHS, how has the issue of interferon-&bgr; prescribing been handled and how are patients with MS faring? Delegates at a recent British Association of Pharmaceutical Physicians meeting*heard from representatives of 1 party involved in this debate - the pharmaceutical industry.

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

Mitoxantrone [‘Novantrone’] is an antineoplastic agent that exerts potent immunomodulatory effects, including suppression of B cell immunity and reduction of T cell numbers. As a consequence, researchers have long since recognised mitoxantrone as a potential research candidate for autoimmune diseases such as multiple sclerosis (MS). A long-term, phase III, European trial demonstrating a mitoxantrone-associated delay in disease progression in patients with progressive MS has recently been highlighted.*These results were further elaborated upon and discussed at the 51st Annual Meeting of the American Academy of Neurology [Toronto, Canada; April 1999].

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

Cisplatin plus paclitaxel has been standard in the first-line treatment of ovarian cancer since the Gynecologic Oncology Group (GOG) 111 trial showed a significant improvement in survival in patients receiving this regimen, compared with cisplatin plus cyclophosphamide, in 1996.*Results from 2 similar large-scale trials in the US and Europe presented at the 35th Annual Meeting of the American Society of Clinical Oncology [Atlanta, US; May 1999] now indicate that carboplatin should replace cisplatin in the platinum/paclitaxel combination for standard treatment. Both trials showed equivalent efficacy and reduced toxicity with carboplatin, and that shortening the infusion time from 24 to 3 hours does not affect efficacy. Carboplatin is also more convenient to administer, with potentially reduced complication rates, reduced hospitalisation rates and reduced costs.

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS